Expert Opinion About the Pharmacoeconomic Edge of Low-Cost Dapagliflozin in Type 2 Diabetes Mellitus in Indian Clinical Settings

• Published in: Curēus (Palo Alto, CA) Vol. 13; no. 11; p. e19194
• Main Authors: Sharma, Kamal, Chandorkar, A B, Kovil, Rajiv, Venkataraman, S, Subrahmanyam, KAV, Mandal, Parthasarathi, Wasir, Jasjeet, Abhyankar, Mahesh, Prasad, Ashish, Sarda, Prashant S
• Format: Journal Article
• Language: English
• Published: Palo Alto Cureus Inc 01.11.2021; Cureus
• Subjects: Antidiabetics; Cost analysis; Diabetes; Endocrinology/Diabetes/Metabolism; Generic drugs; Glucose; Heart failure; Kidney diseases; Metabolism; Mortality; Pharmacoeconomics; Physicians; India
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.19194

BackgroundThis study aimed to understand the attitudes, beliefs, and concerns of physicians across India regarding the economic burden of diabetes and subsequently the cost-effectiveness of low-cost dapagliflozin for the management of patients with uncontrolled type 2 diabetes mellitus (T2DM) on background metformin therapy in Indian clinical settings.MethodA cross-sectional questionnaire survey was conducted among physicians treating people with T2DM with or without complications. The questions covered the general aspects of affordability and adherence to diabetes medications as well as specific details of low-cost dapagliflozin and its cost-effectiveness.ResultsIn total, 844 physicians provided a response to the survey questionnaire. The physicians who participated in the study included diabetologists, endocrinologists, cardiologists, consulting physicians, and family physicians. A majority of the physicians (53%) opined that only 10%-30% of their patients can afford the cost of newer antidiabetic medicines, while 25% of the physicians mentioned that <10% of their patients had issues related to affordability. Further, 39% of the physicians opined that 20%-40% of their patients discontinue the medicines due to high cost. Most of the physicians (95%) agreed that due to the low cost of dapagliflozin, it can be used for the primary prevention of heart failure in patients with T2DM in India. Similarly, 98% of the physicians agreed that it can be used for the treatment of heart failure in patients with or without T2DM in India. A majority of these physicians (93%) responded that switching from expensive sodium/glucose cotransporter-2 inhibitors (SGLT2i) to low-cost dapagliflozin is a long-term cost-effective management of T2DM. In total, 98% of the physicians agreed that low-cost dapagliflozin has the characteristics of an ideal SGLT2i because of its metabolic benefits, cardioprotection, nephroprotection, and potential cost-effectiveness.ConclusionThis survey-based study indicates that dapagliflozin is an effective and cost-saving therapy for patients with T2DM and complications. Low-cost dapagliflozin can revolutionize the treatment of T2DM in the Indian setting.